Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
00:13:00 EDT Mon 29 Apr 2024
Enter Symbol
or Name
USA
CA



News for U:PRPO from 2023-04-30 to 2024-04-29 - 27 items News ReleasesIn The NewsOther CAUS
DateSymPriceTypeHeadline
2024-03-25 17:00U:PRPONews ReleasePrecipio Announces Year end 2023 Shareholder Update Call
2024-02-13 10:00U:PRPONews ReleasePrecipio to Report $15.2M for FY-2023 (unaudited) Revenues, an increase of 60% YoY
2024-02-06 10:00U:PRPONews ReleasePrecipio and Cardinal Health Sign Distribution Agreement for its HemeScreen ‚ ® Portfolio of Molecular assays for Cancer
2024-01-23 10:00U:PRPONews ReleasePrecipio ¢ € ™s Q4-2023 Cash Burn From Operations (unaudited) drops below $100K for the full quarter
2024-01-17 10:30U:PRPONews ReleasePrecipio Signs Distribution Agreement For IV-Cell ‚ ® and HemeScreen ‚ ® in Japan
2024-01-02 09:00U:PRPONews ReleasePrecipio Announces Christina Valauri joins the Board of Directors
2023-12-14 16:30U:PRPONews ReleasePrecipio Management Shares Thoughts on 2023, and Looks Ahead To 2024
2023-11-16 17:00U:PRPONews ReleasePrecipio Announces Q3-2023 Shareholder Update Call
2023-10-18 09:00U:PRPONews ReleasePrecipio to Report $4.5M Q3-2023 Revenues, Double From Q3-2022
2023-10-03 10:00U:PRPONews ReleasePrecipio ¢ € ™s Q3 Cash Burn From Operations (unaudited) Declines 59% YoY, from $2.5M in Q3-2022 to approximately $1M in Q3-2023
2023-09-28 09:00U:PRPONews ReleasePrecipio Continues to Sign New HemeScreen ¢ „ ¢ Customers
2023-09-25 11:00U:PRPONews ReleasePrecipio Reduces Product Revenue Result Needed for Cash Flow Breakeven
2023-09-21 09:00U:PRPONews ReleasePrecipio Takes Final Step Towards Regaining Nasdaq Compliance
2023-09-13 09:30U:PRPONews ReleasePrecipio ¢ € ™s Pathology Division Exceeds Breakeven Revenues in August, Four Months Ahead of Plan
2023-08-10 17:00U:PRPONews ReleasePrecipio Announces Q2-2023 Shareholder Update Call
2023-08-08 09:00U:PRPONews ReleasePrecipio Launches Its Much-Anticipated Quantitative BCR-ABL 2.0 Panel
2023-08-03 09:00U:PRPONews ReleasePrecipio ¢ € ™s Operational Efficiency Measures Continue To Reduce Cash Burn And Move The Company Towards Breakeven
2023-08-01 09:00U:PRPONews ReleasePrecipio Unaudited Q2-2023 Revenues Show combined increase of 25% over Q1-2023
2023-06-14 09:50U:PRPONews ReleasePrecipio ¢ € ™s Omnia ¢ „ ¢ Methodology Enables Diagnosis of MDS With Peripheral Blood Instead of Bone Marrow Biopsy
2023-06-13 09:00U:PRPONews ReleasePrecipio Enters into Collaboration with Prestigious New York-based Institution to Develop Revolutionary Brain Tumor Panel using HemeScreen ‚ ® Technology
2023-06-08 08:30U:PRPONews ReleasePrecipio, Inc. Announces Pricing of $2 Million Registered Direct Offering and Concurrent Private Placement
2023-06-07 09:30U:PRPONews ReleaseProjected cash burn reduced by $1.5 million annually from Three Operational Efficiency Projects
2023-05-22 11:00U:PRPONews ReleasePrecipio ¢ € ™s Lab Detects BCR-ABL1 Oncogene Co-Expression of p190 & p210 Isoforms in a CML Patient By Using HemeScreen ‚ ® Technology
2023-05-17 16:00U:PRPONews ReleasePrecipio Shares Growth Catalysts For HemeScreen
2023-05-15 16:00U:PRPONews ReleasePrecipio Announces Q1-2023 Shareholder Update Call
2023-05-04 13:00U:PRPONews ReleasePrecipio Adds Substantial Pathology Customer to its Diagnostic Services Division
2023-05-04 10:00U:PRPONews ReleasePrecipio Signs Another HemeScreen ¢ „ ¢ Customer